ESC 365 - Finerenone in reducing mortality and morbidity in diabetic kidney disease

Open Access

Finerenone in reducing mortality and morbidity in diabetic kidney disease

Session: Improving cardiovascular and renal outcomes in diabetic kidney disease

Topic: Chronic Kidney Disease

Speaker: Professor G. Filippatos (Athens, GR)

Sponsored by Sciarc GmbH

Event: Heart Failure 2021 Online Congress

Congress Session

About the speaker

Professor Gerasimos Filippatos

National & Kapodistrian University of Athens Medical School, Athens (Greece)

55 presentations

1 follower

3 more presentations in this session

Welcome and introduction.

Speaker: Professor S. Anker (Berlin, DE)

Mineralcorticoid-antagonists in chronic kidney disease and Type 2 Diabetes: Key clinical findings from current studies.

Speaker: Professor R. Schmieder (Erlangen, DE)

Discussion and closure.

Access the full session

Improving cardiovascular and renal outcomes in diabetic kidney disease

Speakers: Professor G. Filippatos, Professor S. Anker, Professor R. Schmieder

About the event

Heart Failure 2021 Online Congress

29 June - 1 July 2021

Sessions Presentations

Congress

Related content

Open Access

An asymptomatic patient with positive treadmill test during screening for life insurance and significant proximal LAD disease in coronary CT angiography: what do the guidelines say?

27 August 2021

Open Access

The ECG and beyond: artificial intelligence will penetrate cardiology practice.

27 August 2021

Open Access

Cardiovascular protection by combination of the selective nonsteroidal MR antagonist finerenone and the SGLT2 inhibitor empagliflozin in a preclinical model of hypertension-induced end-organ damage

27 August 2021

This platform is supported by